Frontiers in Endocrinology

Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment

By Ilaria Milani, Maria Eugenia Parrotta, Marianna Chinucci, Danila Capoccia

Cohort study of 248 peopleInterventions

The paper

Ilaria Milani, Maria Eugenia Parrotta, Marianna Chinucci, Danila Capoccia

Sapienza University of Rome

Frontiers in Endocrinology, 28 Jul 2026

doi.org/10.3389/fendo.2026.1819337 PubMed 42582375

Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity